Butchertown Clinical Trials
 | |
| Privately held company | |
| Industry | |
| Founded | 1984 began clinical trials in 2000, using current name in 2021 |
| Founder | Mark Prussian |
| Headquarters | Louisville, Kentucky |
Key people | Mark Prussian (Founder and CEO) |
| Products | Clinical trial services for pharmaceutical, biotech and medical companies and individuals |
Number of employees | 50 - 75 |
| Parent | Eye Care Institute |
| Website | butchertownclinicaltrials |
Butchertown Clinical Trials is an ophthalmic, vaccine, adult medicine and metabolic disease clinical trials research site in Louisville, Kentucky. It has a national reputation as a superior, fully compliant and high-enrolling ophthalmic trials site.[1]
Butchertown has completed over 350 trials, which have led to FDA approval for fifteen trial drugs and devices. During a period of rapid growth, in 74 Phase 1, 2, 3, and 4 clinical and surgical trials during 2021 and 2022.[2]
With their patient databases, scheduling and clinical trial management software systems, Butchertown Clinical Trial can search 78,000 active patient charts to identify potential trial subjects by condition, disease and other inclusion/exclusion criteria.[3]
History
The Eye Care Institute, the parent company of Butchertown Clinical Trials, began in 1984 with a commitment to serving Louisville area residents in need of quality eye care. Its practice expanded to several offices, offering cutting-edge procedures that kept pace with advances in the field of ophthalmology.
In 2000, The Eye Care Institute expanded its practice to include an embedded clinical trials research site, which they now call Butchertown Clinical Trials. This has led to 15 FDA approvals.[4]
Since 2020, Butchertown Clinical Trials has been participating in over 30 clinical trials per year. Over its history, the program contributed to 15 drugs or medical devices gaining FDA approval. Several applications for approval are now pending before the FDA.[5]
Its clinical trials successes include EYSUVIS™, Durysta™, iStent®, Xiidra®, Hydrus®, True Tear®, Rhopressa®, Inveltys®, Lumigan®, Lotemax®, Vexol®, Visudyne®, Dextenza®, Tyrvaya™, and Vuity™.
Services
The company's primary focus is serving the pharmaceutical and biotechnology industries. As part of its clinical and non-clinical development services, it provides drug development services across all phases of development and multiple therapeutic areas such as artificial intelligence, diabetes, endocrinology, inflammation, family medicine, nutrition, vaccines, ophthalmology, and the development of companion diagnostics, surgical devices, and surgical implants.[6]
Butchertown Clinical Trial conducts clinical studies with the goal of getting the medication, treatment, implant, or device to become approved by the United States Food & Drug Administration (FDA).
Butchertown Clinical Trial is committed to its patients' health, wellness, and vision. It reviews all trials to guarantee the safety and well-being of their Louisville, Kentucky area participants.[7]
Facility
Butchertown Clinical Trial has a freestanding clinical trial building on their 21,000 square feet medical campus. Its facilities include two procedure rooms, two primary care medical examination rooms, 35 ophthalmic examination rooms, twelve diagnostic and imaging rooms, and a designated trial monitor area.
Butchertown Clinical Trial is equipped with dedicated, specially designed, multi-study four-meter ophthalmic examination lanes, featuring Early Treatment Diabetic Retinopathy Study (ETDRS) and electronic visual acuity testing with specialized lighting that meets all protocol requirements.
The site includes several refrigeration options for investigational products, has fully monitored safety and building compliance services, and has a backup generator system.[8]
References
- ↑ "2022 Review: Butchertown Clinical Trials". dallassentinel.com. Retrieved 6 October 2022.
- ↑ "Is Butchertown Clinical Trials a legitimate clinical trial company?". fresnoinquirer.com. Retrieved 6 October 2022.
- ↑ "Butchertown Clinical Trials' extraordinary growth in FY21". philadelphiachronicle.com. Retrieved 6 October 2022.
- ↑ "Butchertown Clinical Trial - Top Ophthalmic Clinical Trial Company in the US". seattledailyobserver.com. Retrieved 6 October 2022.
- ↑ "2022 Review: Butchertown Clinical Trials". sandiegoobserver.com. Retrieved 6 October 2022.
- ↑ "Butchertown Clinical Trial - Top Ophthalmic Clinical Trial Company in the US". bridgeportexaminer.com. Retrieved 6 October 2022.
- ↑ "CEO Spotlight: How Mark Prussian built Butchertown Clinical Trials". airlingtonchronicle.com. Retrieved 6 October 2022.
- ↑ "2022 Review: Butchertown Clinical Trials". nycsun.com. Retrieved 6 October 2022.